Felixvet Launches Carprofen Soft Chewable Tablets

Kansas City, Mo. — April 2, 2025 — As part of its commitment to enhance animal health, Felixvet has successfully launched Carprofen Soft Chewable Tablets, now available through animal health distributors. Felixvet, Inc., a generic companion animal pharmaceutical manufacturer based in Ireland, established its North American headquarters in Kansas City, Missouri, in 2023.

“We are excited to announce the launch of our fifth carprofen product offering in the U.S. market,” said Vince Palasota, President of North America at Felixvet. “This development marks a significant step forward in providing quality, affordable healthcare solutions for pets without sacrificing efficacy, safety or reliability.”

Felixvet is leading the animal health market by introducing Carprofen Soft Chewable Tablets to its portfolio of carprofen products. This addition offers veterinarians five different forms of carprofen, each specifically designed to meet the diverse needs of their customers. 

“We are committed to introducing additional products that will help us become one of the leading companion animal generic drug companies globally,” states Palasota.

Carprofen Soft Chewable Tablets provide the same therapeutic benefits as other branded carprofen medications, but the new beef flavored Felixvet Soft Carprofen Chewable Tablets offer a state of the art, unique soft chewable tablet compared to the hard chewable tablet pioneer, RIMADYL^®. They are easy to administer orally due to the palatable beef flavor. Felixvet’s Soft Chewable technology is based on traditional compression technology without the constraints imposed by current production processes such as extrusion or molding.

A nonsteroidal anti-inflammatory, Carprofen Soft Chewable Tablets relieve pain and inflammation associated with osteoarthritis. The tablets are therapeutically equivalent to the pioneer drug, RIMADYL^®, with the same safety and efficacy. Available in three strengths, 25, 75 and 100 mg, each tablet is scored for easy and accurate dosing.

For more information, visit Felixvet.com or info@felixvetus.com.

About Felixvet: 
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com